

ASX/Media Release

17/09/2020

Emerald partners with Mt Sinai for Openly service

- **Emerald has partnered with Mt Sinai Hospital’s Precision Recovery team, based in New York, to support ongoing development of Emerald’s Openly clinical service**
- **Mt Sinai to support remote monitoring of patients and care coordination**
- **Engagement with Mt Sinai follows recent successful TGA registration of Openly platform**

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence data company that develops remote patient monitoring technologies, is pleased to announce it has entered into a professional services agreement with the Precision Recovery team at New York’s Mt Sinai Hospital, one of the leading teaching and research hospitals in the United States. The Precision Recovery Team is currently managing over 1,600 COVID-positive, COVID-suspected and COVID-recovering individuals remotely and has special expertise in this area.

Under the agreement, Mt Sinai’s Precision Recovery team will provide remote monitoring and consulting services to support the development and delivery of Emerald’s Openly clinical service worldwide, in exchange for access to the Openly app and a payment for any alert reviewed by the Mt Sinai team on request.

Openly is a digital health and wellness screening service provided via smart mobile devices and backed by Emerald’s clinical team. As announced on 15 September 2020, the Openly platform has recently been registered as a Class 1 medical device with the Australian Therapeutic Goods Administration (TGA).

Alerts may be generated by the Openly platform when certain survey responses or other health information is entered by the user. The criteria for generating alerts are configured uniquely for each client and updated by Emerald’s clinical experts as more data is acquired by the system. Alert review requests made to the Precision Recovery team are to be initiated at the discretion of Emerald’s clinical team. The Company does not anticipate the financial consideration of this aspect of the agreement to be material.

Assistant Professor David Putrino, Director of the Precision Recovery Team at Mount Sinai and 2019 Advance Global Australian Overall Award winner said the COVID-19 pandemic had presented a considerable challenge to healthcare providers providing remote clinical services.

“COVID-19 has fundamentally changed the way that we provide high quality medical care and thrust the use of technology in healthcare to the forefront. Where possible, management of mild to moderate COVID cases should happen in the home, and we have been working to develop innovative technologies and clinician workflows that enable healthcare professionals to keep sick patients safe at home.”

Emerald’s CEO, Dr Michael Winlo said the agreement with Mt Sinai will improve the health and wellness screening services that can be delivered on the Openly platform to support workforces get back to business.

“This agreement allows Emerald to benefit from the real-world experiences and expertise of the Precision Recovery team which will help enhance the capabilities of the Openly technology as well as the health screening services our clinical team can deliver. We’re thrilled to be working with such an innovative and world-leading organisation to advance remote patient care.”

Release authorised by: Dr Michael Winlo, CEO and Managing Director

For further information:

Dr Michael Winlo
CEO
(08) 6559 2800
investors@emeraldclinics.com.au

Matt Wright
Media/investor relations
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About Emerald Clinics Limited

Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald's evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.